Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All famotidine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients with COVID-19 in Taiwan: A Retrospective Study

Lin et al., International Journal of Gerontology, doi:10.6890/IJGE.202307_17(3).0008
Jul 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Famotidine for COVID-19
26th treatment shown to reduce risk in October 2021
 
*, now with p = 0.00028 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Retrospective 171 hospitalized patients in Taiwan, showing no signficant differences with famotidine, but a trend towards lower ICU admission. However, authors present only unadjusted results with groups that are not very comparable for ICU/mortality outcomes (e.g., 24% vs. 10% had ordinal score ≥5 at baseline), without mentioning the differences (they note only "confounding due of unobserved factors").
This study is excluded in meta analysis: significant unadjusted confounding factors.
Lin et al., 1 Jul 2023, retrospective, Taiwan, peer-reviewed, 4 authors, study period 1 May, 2021 - 31 August, 2021.
This PaperFamotidineAll
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients with COVID-19 in Taiwan: A Retrospective Study
Hsiang-Ling Lin, Yu-Ning Winter, Lee, Fang-Ju Sun, Ming-Wei Cheng, S U M M A R Y
doi:10.6890/IJGE.202307_17(3).0008
The aim of this study was to investigate the association between famotidine treatment and severity, as well as mortality, for patients with COVID-19. In addition, to investigate whether this association was changed in cases of concomitant treatment with corticosteroids, remdesivir, clarithromycin, low molecular weight heparin, or statin. Material and methods: This is a retrospective cohort study conducted by analyzing electronic medical records of 171 hospitalized patients into the Infectious Disease Ward of a 2068-bed tertiary care medical center, with laboratory-confirmed COVID-19 between May 01, 2021 and August 31, 2021. Patients were classified as receiving famotidine if they were treated with oral drug, at any dose, within ± 7 days of COVID-19 screening and/or hospital admission. Famotidine use was extracted directly from the electronic medical record. Results: Current study failed to identify famotidine as a protective factor associated with a significant reduction in the risk of in-hospital mortality (odds ratio 1.573, 95% confidence interval (CI) 0.464-5.325, p = 0.467) or a significant reduction in the risk of ICU admission (odds ratio 0.547, 95% confidence interval (CI) 0.286-1.045, p = 0.068). However, non-significant trend towards a lower rate of ICU admission in association with famotidine prescription was observed. Conclusions: The results of this study reflect the real-world use of famotidine does not reduce the risk of in-hospital-mortality or ICU admission of hospitalized COVID-19 patients.
References
Anand, Ziebuhr, Wadhwani, Mesters, Hilgenfeld, Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs, Science, doi:10.1126/science.1085658
Birch, Molinar-Inglis, Trejo, Subcellular hot spots of GPCR signaling promote vascular inflammation, Curr Opin Endocr Metab Res, doi:10.1016/j.coemr.2020.07.011
Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents, Life Sci, doi:10.1016/s0024-3205(96)00553-x
Cheung, Hung, Leung, Association between famotidine use and COVID-19 severity in Hong Kong: A territory-wide study, Gastroenterology, doi:10.1053/j.gastro.2020.05.098
Chiu, Shen, Lo, Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis, PLoS One, doi:10.1371/journal.pone.0259514
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterology, doi:10.1053/j.gastro.2020.05.053
Harapan, Itoh, Yufika, Coronavirus disease 2019 (COVID-19): A literature review, J Infect Public Health, doi:10.1016/j.jiph.2020.03.019
Ii, Iii, Cannon, Dual-histamine receptor blockade with cetirizine -famotidine reduces pulmonary symptoms in COVID-19 patients, Pulm Pharmacol Ther, doi:10.1016/j.pupt.2020.101942
Kritas, Ronconi, Caraffa, Gallenga, Ross et al., Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy, J Biol Regul Homeost Agents, doi:10.23812/20-Editorial-Kritas
Krystel-Whittemore, Dileepan, Wood, Mast cell: A multi-functional master cell, Front Immunol, doi:10.3389/fimmu.2015.00620
Kuno, So, Takahashi, Egorova, The association between famotidine and in-hospital mortality of patients with COVID-19, J Med Virol, doi:10.1002/jmv.27375
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105924
Li, Dong, Lei, No evidence indicates famotidine reduces the risk of serious disease in COVID-19 patients after propensity score matching: Meta-analysis and systematic reviews, Dig Dis Sci, doi:10.1007/s10620-021-07214-9
Malone, Tisdall, Smith, COVID-19: Famotidine, histamine, mast cells, and mechanisms, Front Pharmacol, doi:10.3389/fphar.2021.633680
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am J Gastroenterol, doi:10.14309/ajg.0000000000000832
Shoaibi, Fortin, Weinstein, Berlin, Ryan, Comparative effectiveness of famotidine in hospitalized COVID-19 patients, Am J Gastroenterol, doi:10.14309/ajg.0000000000001153
Sun, Chen, Hu, Does famotidine reduce the risk of progression to severe disease, death, and intubation for COVID-19 patients? A systemic review and meta-analysis, Dig Dis Sci, doi:10.1007/s10620-021-06872-z
Wiersinga, Rhodes, Cheng, Peacock, Prescott, Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review, JAMA, doi:10.1001/jama.2020.12839
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B, doi:10.1016/j.apsb.2020.02.008
{ 'issue': '3', 'page-first': '183', 'author': [ {'literal': 'Hsiang-Ling Lin'}, {'literal': 'Winter Yu-Ning Lee'}, {'literal': 'Fang-Ju Sun'}, {'literal': 'Ming-Wei Cheng'}], 'ISSN': '1873-9598', 'language': 'en', 'abstract': 'Objectives: The aim of this study was to investigate the association between famotidine ' 'treatment and severity, as well as mortality, for patients with COVID-19. In addition, to ' 'investigate whether this association was changed in cases of concomitant treatment with ' 'corticosteroids, remdesivir, clarithromycin, low molecular weight heparin, or statin. ' 'Material and methods: This is a retrospective cohort study conducted by analyzing electronic ' 'medical records of 171 hospitalized patients into the Infectious Disease Ward of a 2068-bed ' 'tertiary care medical center, with laboratory-confirmed COVID-19 between May 01, 2021 and ' 'August 31, 2021. Patients were classified as receiving famotidine if they were treated with ' 'oral drug, at any dose, within ± 7 days of COVID-19 screening and/or hospital admission. ' 'Famotidine use was extracted directly from the electronic medical record. Results: Current ' 'study failed to identify famotidine as a protective factor associated with a significant ' 'reduction in the risk of in-hospital mortality (odds ratio 1.573, 95% confidence interval ' '(CI) 0.464-5.325, p = 0.467) or a significant reduction in the risk of ICU admission (odds ' 'ratio 0.547, 95% confidence interval (CI) 0.286-1.045, p = 0.068). However, non-significant ' 'trend towards a lower rate of ICU admission in association with famotidine prescription was ' 'observed. Conclusions: The results of this study reflect the real-world use of famotidine ' 'does not reduce the risk of in-hospital-mortality or ICU admission of hospitalized COVID-19 ' 'patients.', 'type': 'article-journal', 'title': 'Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients with COVID-19 in Taiwan: ' 'A Retrospective Study', 'URL': '', 'volume': '17', 'container-title': 'International Journal of Gerontology', 'issued': {'date-parts': [['2023', '7', '1']]}, 'DOI': '10.6890/IJGE.202307_17(3).0008'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit